Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment.

(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Morris provided a summary of the PSMAfore trial in progress (NCT04689828). This ...

PSMA and Beyond 2025 antibody drug development (ADC) in prostate cancer, ADC program in advance prostate cancer, PSMA expression, ...

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...

(UroToday.com) The 2025 PSMA and Beyond annual meeting featured a PSMA session and a presentation by Dr. Wolfgang Fendler discussing PSMA-PET for overall survival outcome risk stratification of ...

SNMMI 2025, PROSTATE CANCER, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Artificial Intelligence-based Risk Score for Prostate Cancer on PSMA PET/CT.

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, was host to the Poster Session: Genitourinary Cancer - Prostate, Testicular, and Penile Cancer.

(UroToday.com) Most patients newly diagnosed with bladder cancer have non-muscle invasive disease (NMIBC). For patients with intermediate or high-risk NMIBC and those with carcinoma in situ (CIS), ...